Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Current status of clozapine in the United States.

Kelly DL, Wehring HJ, Vyas G.

Shanghai Arch Psychiatry. 2012 Apr;24(2):110-3. doi: 10.3969/j.issn.1002-0829.2012.02.007. No abstract available.

2.

Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems.

Sun F, Stock EM, Copeland LA, Zeber JE, Ahmedani BK, Morissette SB.

Am J Health Syst Pharm. 2014 May 1;71(9):728-38. doi: 10.2146/ajhp130471.

3.

Validation of a claims-based antipsychotic polypharmacy measure.

Leckman-Westin E, Kealey E, Gupta N, Chen Q, Gerhard T, Crystal S, Olfson M, Finnerty M.

Pharmacoepidemiol Drug Saf. 2014 Jun;23(6):628-35. doi: 10.1002/pds.3609. Epub 2014 Mar 24.

4.

Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment.

Toteja N, Gallego JA, Saito E, Gerhard T, Winterstein A, Olfson M, Correll CU.

Int J Neuropsychopharmacol. 2014 Jul;17(7):1095-105. doi: 10.1017/S1461145712001320. Epub 2013 May 14. Review.

5.

Antipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales.

Kishimoto T, Watanabe K, Uchida H, Mimura M, Kane JM, Correll CU.

Psychiatry Res. 2013 Oct 30;209(3):406-11. doi: 10.1016/j.psychres.2013.03.014. Epub 2013 Apr 18.

6.

Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Correll CU, Gallego JA.

Psychiatr Clin North Am. 2012 Sep;35(3):661-81. doi: 10.1016/j.psc.2012.06.007. Epub 2012 Jul 24. Review.

7.

Antipsychotic polypharmacy in a regional health service: a population-based study.

Bernardo M, Coma A, Ibáñez C, Zara C, Bari JM, Serrano-Blanco A.

BMC Psychiatry. 2012 May 15;12:42. doi: 10.1186/1471-244X-12-42.

8.

Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU.

Schizophr Res. 2012 Jun;138(1):18-28. doi: 10.1016/j.schres.2012.03.018. Epub 2012 Apr 24. Review.

9.

The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?

Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR.

Schizophr Bull. 2011 Nov;37(6):1209-17. doi: 10.1093/schbul/sbq038. Epub 2010 Apr 21.

10.

A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.

Honer WG, Procyshyn RM, Chen EY, MacEwan GW, Barr AM.

J Psychiatry Neurosci. 2009 Nov;34(6):433-42. Review.

11.

Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study.

Kroken RA, Johnsen E, Ruud T, Wentzel-Larsen T, Jørgensen HA.

BMC Psychiatry. 2009 May 16;9:24. doi: 10.1186/1471-244X-9-24.

12.

Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use.

Pickar D, Vinik J, Bartko JJ.

PLoS One. 2008 Sep 10;3(9):e3150. doi: 10.1371/journal.pone.0003150.

13.

Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.

Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S.

Schizophr Bull. 2009 Mar;35(2):443-57. doi: 10.1093/schbul/sbn018. Epub 2008 Apr 15.

14.

Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns.

Kreyenbuhl JA, Valenstein M, McCarthy JF, Ganoczy D, Blow FC.

Psychiatr Serv. 2007 Apr;58(4):489-95.

15.

Does antipsychotic polypharmacy increase the risk for metabolic syndrome?

Correll CU, Frederickson AM, Kane JM, Manu P.

Schizophr Res. 2007 Jan;89(1-3):91-100. Epub 2006 Oct 27.

Supplemental Content

Support Center